Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
Type:
Application
Filed:
May 11, 2023
Publication date:
April 18, 2024
Applicant:
ACTIVE BIOTECH AB
Inventors:
Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
Abstract: Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
Type:
Application
Filed:
September 7, 2022
Publication date:
March 2, 2023
Applicant:
Active Biotech AB
Inventors:
Helena Eriksson, Joel Kaye, Marie Törngren
Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
Type:
Grant
Filed:
July 2, 2021
Date of Patent:
October 25, 2022
Assignee:
Active Biotech AB
Inventors:
Helena Eriksson, Joel Kaye, Marie Törngren
Abstract: The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.
Type:
Application
Filed:
July 2, 2021
Publication date:
October 21, 2021
Applicant:
Active Biotech AB
Inventors:
Helena Eriksson, Joel Kaye, Marie Törngren
Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
Type:
Application
Filed:
December 17, 2019
Publication date:
April 30, 2020
Applicant:
ACTIVE BIOTECH AB
Inventors:
Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder, an autoimmunity disorder or a neurodegenerative disorder.
Type:
Grant
Filed:
December 4, 2015
Date of Patent:
August 20, 2019
Assignee:
Active Biotech AB
Inventors:
Ulf Wellmar, Stephen East, Marie Bainbridge, Colin MacKinnon, James Carr, Jonathan Hargrave
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
November 13, 2018
Assignee:
Active Biotech AB
Inventors:
Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Type:
Grant
Filed:
May 14, 2014
Date of Patent:
January 23, 2018
Assignee:
Active Biotech AB
Inventors:
Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Type:
Grant
Filed:
May 22, 2015
Date of Patent:
September 26, 2017
Assignee:
Active Biotech AB
Inventors:
Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
Abstract: Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl) -phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease.
Abstract: A method for preparing a compound of formula (I) by reacting the appropriate alkyl ester and an aniline derivative, in a refluxing mixture containing an aliphatic solvent or a mixture of aliphatic solvents having a boiling point in the range of 68-191° C.; condensing vapors of the refluxing mixture; treating the condensed vapors with an alcohol scavenging agent or a mixture of alcohol scavenging agents; and returning the condensed vapors back to the reaction mixture.
Type:
Grant
Filed:
July 7, 2011
Date of Patent:
October 28, 2014
Assignee:
Active Biotech AB
Inventors:
Lillemor Maria Bock, Par Henning Holmberg, Karl-Erik Jansson
Abstract: A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:—determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or—determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
Type:
Grant
Filed:
April 24, 2008
Date of Patent:
September 23, 2014
Assignee:
Active Biotech, AB
Inventors:
Per Bjork, Frederik Ivars, Tomas Leanderson
Abstract: A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
June 17, 2014
Assignee:
Active Biotech AB
Inventors:
Karl Jansson, Tomas Fristedt, Hans Wannman, Anders Bjork
Abstract: Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease.
Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
October 1, 2013
Assignees:
Teva Pharmaceutical Industries, Ltd., Active Biotech, AB
Inventors:
Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson